Beacon Equity issues Technical Trading Overview for XOMA Ltd.
The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
(EMAILWIRE.COM, October 01, 2009 ) DALLAS, Texas - BeaconEquity.com announces an investment report featuring biopharmaceutical company XOMA Ltd. (Nasdaq: XOMA).
The investment report on XOMA Ltd. (Nasdaq: XOMA) should be of particular interest to other biopharmaceutical companies: Amgen Inc. (Nasdaq: AMGN), Emergent BioSolutions Inc. (NYSE: EBS) and Wyeth (NYSE: WYE).
It is available at: http://www.beaconequity.com/i/XOMA
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
XOMA Ltd. (XOMA) is a biopharmaceutical company focused on the discovery, development and manufacture of therapeutic antibodies. XOMA uses its expertise, technologies and capabilities to build a product pipeline that includes multiple collaborative development programs.
In the report, the analyst notes:
In the second quarter, XOMA achieved a key goal by completing the second and third parts of the XOMA 052 U.S. phase I trial in patients with type 2 diabetes. The Company reported positive results after three doses out to the last day of the study, demonstrating a favorable safety profile and clinically meaningful improvements in diabetic and inflammatory measures. According to the Company, the first evidence of improved peripheral insulin sensitivity was observed.
On September 15, 2009, XOMA received a letter from the NASDAQ Stock Market indicating that for the preceding 30 consecutive business days, the bid price of the Company's common shares closed below the minimum $1 per share requirement pursuant to NASDAQ Marketplace Rule 4450(a)(5) for continued inclusion on the NASDAQ Global Market. If the Company does not regain compliance by March 15, 2010, NASDAQ would provide written notification that the Company's common shares will be delisted, after which the Company may appeal to the NASDAQ Listing Qualifications Panel.
To read the entire report visit: http://www.beaconequity.com/i/XOMA
See what investors are saying about these stocks at: http://www.stockhideout.com/
BeaconEquity.com is one of the industry's largest small-cap report providers, providing a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. BeaconEquity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
The investment report on XOMA Ltd. (Nasdaq: XOMA) should be of particular interest to other biopharmaceutical companies: Amgen Inc. (Nasdaq: AMGN), Emergent BioSolutions Inc. (NYSE: EBS) and Wyeth (NYSE: WYE).
It is available at: http://www.beaconequity.com/i/XOMA
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
XOMA Ltd. (XOMA) is a biopharmaceutical company focused on the discovery, development and manufacture of therapeutic antibodies. XOMA uses its expertise, technologies and capabilities to build a product pipeline that includes multiple collaborative development programs.
In the report, the analyst notes:
In the second quarter, XOMA achieved a key goal by completing the second and third parts of the XOMA 052 U.S. phase I trial in patients with type 2 diabetes. The Company reported positive results after three doses out to the last day of the study, demonstrating a favorable safety profile and clinically meaningful improvements in diabetic and inflammatory measures. According to the Company, the first evidence of improved peripheral insulin sensitivity was observed.
On September 15, 2009, XOMA received a letter from the NASDAQ Stock Market indicating that for the preceding 30 consecutive business days, the bid price of the Company's common shares closed below the minimum $1 per share requirement pursuant to NASDAQ Marketplace Rule 4450(a)(5) for continued inclusion on the NASDAQ Global Market. If the Company does not regain compliance by March 15, 2010, NASDAQ would provide written notification that the Company's common shares will be delisted, after which the Company may appeal to the NASDAQ Listing Qualifications Panel.
To read the entire report visit: http://www.beaconequity.com/i/XOMA
See what investors are saying about these stocks at: http://www.stockhideout.com/
BeaconEquity.com is one of the industry's largest small-cap report providers, providing a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. BeaconEquity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
Contact Information:
Beacon Equity
Jeff Bishop
Tel: (469)-252-3505
Email us
This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.
Beacon Equity
Jeff Bishop
Tel: (469)-252-3505
Email us
This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.
|
Private Equity, Angel Investing
Equity Alliance / Private Equity, Angel Investing, / IPO, Venture Capital & IR services / Equity Alliance International Equityallianceir.com Penny Stocks to Watch Sign up for hot penny stock picks Gains of 500%+ possible! Premiumstockpicks.com/landing/ Your text Ads & PR Text Ads plus unlimited press releases, One release featured/Day for only $575 per month. Read more on Text Ads & PR Your text Ads Here! Text Ads are only $289 per month. Ads are placed same day. More on Text Ads Advertising |